AGP Executive Report
Last update: 5 hours agoHepatitis B: The FDA approved bepirovirsen, the first antisense therapy for chronic hepatitis B. In trials, some patients achieved a functional cure after a six-month course, offering a new option for a disease affecting more than 240 million people worldwide. Ebola Response: Kenya says all eight surviving patients are stable and improving, with 134 of 135 contacts traced. A Nigerian health professor warned that severe staffing shortages could hamper the response. Women’s Health: A review linked hormone therapy in postmenopausal women to more frequent migraines, but not more severe attacks; researchers caution the association may not be caused by treatment. Mental Health: A free online program reduced depression relapse risk by double digits among expectant and new mothers with a history of depression, offering a potential alternative for those facing barriers to therapy. Alzheimer’s Research: The FDA granted Fast Track status to an experimental vaccine designed to prevent Alzheimer’s in people with early biological signs of the disease; it remains under investigation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Now is the time to get ready for 2027 changes in prior authorization, MA Star Ratings and others in federal healthcare law and regulations]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29643181-951375703-77295c823d8410e21e01a0a0f3320e5184842ef7-1200x675-200x113.jpeg)
